SCYNEXIS

SCYNEXIS, Inc. is a biotechnology company engaged in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Scynexis, Inc. (“Scynexis” or the “Company”) (NASDAQ: SCYX) investors concerning the Company's possible violations of federal securities laws. On September 25, 2023, Scynexis disclosed that it would be recalling ibrexafungerp tablets from the market and placing a temporary hold on clinical studies of ibrexafungerp due to a recent review finding that “a non-antibacterial beta-lactam drug substa.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Scynexis, Inc. (SCYX) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Scynexis, Inc. (“Scynexis” or the “Company”) (NASDAQ: SCYX) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Scynexis investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Scynexis, Inc. (SCYX) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Scynexis, Inc. (“Scynexis” or the “Company”) (NASDAQ: SCYX) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On September 25, 2023, Scynexis disclosed that it would be recalling ibrexafungerp tablets from the market and placing a temporary hold on clinical studies of ibrexafungerp due.

The Law Offices of Frank R. Cruz Announces Investigation of Scynexis, Inc. (SCYX) on Behalf of Investors

SCYNEXIS' (SCYX) shares soar 134% year to date, owing to partnership with big wig GSK plc for the development of its antifungal tablet, Brexafemme.

SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why

Aqua Metals

Cidara Therapeutics

As a rule of thumb, you should stay away from penny stocks. When you see shares priced near a buck (or even below), there's usually a reason for it – and not a good one.

Want to Get Rich? 3 Game-Changing Penny Stocks to Buy Right Now

JERSEY CITY, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that management will participate in the following investor conferences.

SCYNEXIS to Participate in September Investor Conferences

JERSEY CITY, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the second quarter ended June 30, 2023.

SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update

These new appointments bring extensive US and international experience in company leadership and development of anti-infectives from R&D to commercialization. These new appointments bring extensive US and international experience in company leadership and development of anti-infectives from R&D to commercialization.

AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti

JERSEY CITY, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that China's National Medical Products Administration (NMPA) has accepted for review a New Drug Application (NDA) for oral ibrexafungerp tablets for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC) in the Chinese mainland. The application was submitted by partner Hansoh Pharmaceutical Group Company Limited (3692.HK), one of the leading biopharmaceutical companies in China, and is based on positive results from Phase 3 studies in which ibrexafungerp successfully achieved statistically significant superiority over placebo for the primary and key secondary study endpoints.

SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China

JERSEY CITY, N.J., June 21, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the achievement of a $25 million performance-based development milestone under its exclusive license agreement with GSK for ibrexafungerp. The milestone payment follows a development goal for the Phase 3 MARIO study for ibrexafungerp in invasive candidiasis as SCYNEXIS continues executing ongoing ibrexafungerp trials. More details on the MARIO trial can be found here (NCT05178862).

SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK

NEW YORK , June 20, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of SCYNEXIS, Inc. (NASDAQ: SCYX). If you are a shareholder of SCYNEXIS, Inc. and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: https://pjlfirm.com/scynexis-inc/ You may also contact Robert H.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating SCYNEXIS, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

JERSEY CITY, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that David Angulo, President and Chief Executive Officer, will take part in a fireside chat at the upcoming Maxim Group Virtual Healthcare Conference on Tuesday, June 20th at 12:30 P.M. ET.

SCYNEXIS to Participate in the Maxim Group Virtual Healthcare Conference

SCYX's 1Q23 earnings highlights steadily underwhelming ibrexafungerp sales, with substantial growth expected in 2024/2025 once GSK begins promotion. Phase 3 MARIO trial data, pivotal for potential label expansion, is anticipated in 1H'24. The study focuses on invasive candidiasis patients.

Scynexis: A Disappointing Q1 Earnings And Cooling GSK Catalyst - We Maintain Neutral Rating

T2 Biosystems

Cranford, New Jersey--(Newsfile Corp. - May 19, 2023) - WBB Research Institute (WBBRI) hosted a Demi-Colton Virtual Salon on the need for a global response to Candida auris and other deadly pathogens. Antimicrobial resistant C.

WBB Research Institute Webcast Highlighted the Need For a Global Response to Candida auris and Other Deadly Antimicrobial Resistant Pathogens

JERSEY CITY, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the closing of its previously announced exclusive license agreement with GSK plc (LSE/NYSE: GSK) to commercialize the novel antifungal BREXAFEMME® (ibrexafungerp tablets) as a treatment for vulvovaginal candidiasis (VVC) and further develop ibrexafungerp for multiple indications in invasive and life-threatening fungal diseases.

SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)

Scynexis (SCYX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.51 per share a year ago.

Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates

JERSEY CITY, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of interim data across a diverse array of infection types from its ongoing Phase 3 FURI and CARES studies, as well as the innovative study design of its ongoing Phase 3 MARIO trial of oral ibrexafungerp treatment after an intravenous (IV) echinocandin, at the 33rd Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held in Copenhagen, Denmark, April 15-18, 2023.

SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark

Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also continue to develop ibrexafungerp for treating invasive candidiasis.

Scynexis (SCYX) Inks Antifungal Drug Deal With GSK

GSK and SCYNEXIS signed an exclusive licensing agreement for Brexafemme, an FDA-approved medicine for vulvovaginal candidiasis. GSK will pay SCYNEXIS $90 million upfront, with additional milestone payments and royalties. SCYNEXIS retains rights to other assets derived from Brexafemme.

Scynexis: Licensing Deal With GSK, Upgrading To A Hold Rating From A Sell

JERSEY CITY, N.J., March 31, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the fourth quarter and full year ended on December 31, 2022.

SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Crown ElectroKinetics

Exela Technologies

Use these tips to identify penny stocks opportunities The post Penny Stocks: Technical Approach to Finding Opportunities  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks: Technical Approach to Finding Opportunities

Scynexis (NASDAQ: SCYX ) stock is taking off on Tuesday as investors react to news of an exclusive license agreement for Brexafemme. Brexafemme is an antifungal for the treatment of vulvovaginal candidiasis and the reduction of the incidence of recurrent VVC.

Why Is Scynexis (SCYX) Stock Up 69% Today?

LONDON and JERSEY CITY, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- GSK plc (LSE/NYSE: GSK) and SCYNEXIS, Inc. (NASDAQ: SCYX), today announced they have entered into an exclusive licence agreement for Brexafemme (ibrexafungerp tablets), a US FDA approved, first-in-class antifungal for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC (RVVC). This exclusive licence agreement gives GSK rights to commercialise Brexafemme for VVC and RVVC while continuing to develop ibrexafungerp, which is in phase III clinical trials for the potential treatment of invasive candidiasis (IC), a life-threatening fungal infection.

GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection

JERSEY CITY, N.J., Nov. 30, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that researchers from Case Western Reserve University in Cleveland have been awarded a competitive research grant of more than $3 million by the National Institutes of Health (NIH), to investigate a second generation fungerp (SCY-247) developed by SCYNEXIS as a potential treatment for Candida auris (C.auris), a multidrug-resistant yeast that causes serious and often deadly infections.

SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant Fungi

JERSEY CITY, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today applauded action taken this week by the Biomedical Advanced Research and Development Authority (BARDA) to add to the areas of interest in its new Broad Agency Announcement (BAA) the development of antifungal Medical Countermeasures (MCM) to treat infections caused by drug-resistant fungal threats. For the first time, BARDA announced this week it is seeking partnerships to develop broad-spectrum next-generation antifungal drugs to treat high-priority fungal infections.

SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats

News for SCYNEXIS Stock (SCYX)